LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

MabDesign joins EuropaBio: innovation linked to the industrial field of biotherapy

14/12/2021
PRESS RELEASE

MabDesign joins EuropaBio: innovation linked to the industrial field of biotherapy

Brussels, 14 December 2021 – EuropaBio is pleased to announce that MabDesign has joined as an associate member. MabDesign, the French biotherapy industrial association, aims to support, federate and increase the visibility of the biopharmaceutical industry since the R&D phases until bioproduction and clinical phases, foster exchanges, promote the development and competitiveness of companies, and stimulate innovation by encouraging the emergence of start-ups from academic research.

In order to carry out its development strategy and to adapt to changes in the industrial ecosystem, MabDesign’s governance is composed of DBV Technologies, Lyonbiopole, Pierre Fabre, Sanofi, ABL Europe, bioMérieux, Institut Pasteur, Thermo Fisher Scientific and TreeFrog Therapeutics as well as three Qualified Persons with Nicola Beltramineli (Lysogene), Hervé Broly (Merck) and Stéphane Legastelois (33 California). The diversity of MabDesign’s board of directors allows to closely follow the needs and challenges of the industrial biotherapy sector.

MabDesign currently counts with more than 215 member companies.

EuropaBio Director-General Dr. Claire Skentelbery commented “MabDesign represents the future of European advanced medicines, with an extensive network of companies from start-ups through to multi-nationals. The innovation base and strength of such a community helps EuropaBio to support Europe’s development as a world leader in advanced therapeutics for patients”.

Nicolas Groux, CEO at MabDesign, added: “We are glad to be part of EuropaBio and we believe that by joining the association we can voice up the expertise that our members have and it will contribute to promote exchanges and collaborations at the European level”.

MabDesign joins EuropaBio


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

11/07/2025

Industrial Decarbonisation Accelerator Act – EuropaBio Position


Read more
07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more

Important links

  • Industrial Decarbonisation Accelerator Act – EuropaBio Position
  • EuropaBio Position on the Critical Medicines Act

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.